Literature DB >> 8547135

Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission.

N Satake1, N Maseki, T Kozu, A Sakashita, H Kobayashi, M Sakurai, M Ohki, Y Kaneko.   

Abstract

In a study of 23 patients with t(8;21)-associated acute myeloid leukaemia the AML1-MTG8 fusion transcript was present in the majority of serial samples obtained from 17 patients followed for up to 34 months after diagnosis, but was absent in samples from all six patients who had been in continuous complete remission for 61 months after allogeneic bone marrow transplantation (BMT), or for 52, 53, 123, 182 and 198 months, respectively, after courses of intensive chemotherapy. Previous studies showed that the AML1-MTG8 fusion transcript was present in most patients with this type of translocation in long-term remission. Our results indicate that blood cells of patients with t(8;21) in remission of over 10 years may not show the AML1-MTG8 fusion transcript, and that those of patients who have undergone allogeneic BMT or intensive chemotherapy may become fusion transcript-negative much earlier. Our study suggests that leukaemic cells with the AML1-MTG8 fusion transcript may survive for some time after courses of chemotherapy or BMT, but that they may eventually be eradicated by immunologic and other antileukaemic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547135     DOI: 10.1111/j.1365-2141.1995.tb05406.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Comparison of spatial chromosomal organization between bone marrow and peripheral blood in acute myeloid leukemia.

Authors:  Xueli Tian; Yanfang Wang; Yu Liu; Jun Yin; Dieyan Chen; Xiaoyan Ke; Wanyun Ma
Journal:  Oncol Lett       Date:  2018-07-27       Impact factor: 2.967

2.  Recurrence of acute myelogenous leukemia with the same AML1/ETO breakpoint as at diagnosis after complete remission lasting 15 years: analysis of stored bone marrow smears.

Authors:  Norifumi Tsukamoto; Masamitsu Karasawa; Yoko Tanaka; Akihiko Yokohama; Hideki Uchiumi; Takafumi Matsushima; Hirokazu Murakami; Yoshihisa Nojima
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

3.  Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22).

Authors:  Lixia Zhang; Qinghua Li; Wei Li; Bingcheng Liu; Ying Wang; Dong Lin; Chunlin Zhou; Chengwen Li; Jianxiang Wang; Yingchang Mi
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

4.  Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia.

Authors:  John A Liu Yin; Lindsay Frost
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

5.  A Comparison of Target Gene Silencing using Synthetically Modified siRNA and shRNA That Express Recombinant Lentiviral Vectors.

Authors:  P V Spirin; D Baskaran; P M Rubtsov; M A Zenkova; V V Vlassov; E L Chernolovskaya; V S Prassolov
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

Review 6.  A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges.

Authors:  Hassan Awada; Moaath K Mustafa Ali; Bicky Thapa; Hussein Awada; Leroy Seymour; Louisa Liu; Carmelo Gurnari; Ashwin Kishtagari; Eunice Wang; Maria R Baer
Journal:  Cancers (Basel)       Date:  2022-08-28       Impact factor: 6.575

7.  Abnormalities of the FHIT transcripts in osteosarcoma and Ewing sarcoma.

Authors:  S Hinohara; N Satake; K Sekine; Y Kaneko
Journal:  Jpn J Cancer Res       Date:  1998-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.